FUZEON (enfuvirtide, T-20). Breaking barriers or breaking the bank?
Matt
M
Sharp
Rob
R
Camp
D019380:Anti-HIV Agents / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D016527:Drug Costs; D000077560:Enfuvirtide; D015700:HIV Envelope Protein gp41 / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy*; D006297:Health Services Accessibility; D006801:Humans; D010349:Patient Compliance; D010446:Peptide Fragments / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*
D019380:Anti-HIV Agents; D015700:HIV Envelope Protein gp41; D010446:Peptide Fragments; D000077560:Enfuvirtide